Clinphone nets founders pounds 3.3m
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Two former hospital doctors who set up a company a year ago aimed at revolutionising clinical trials for new drugs will both pocket over pounds 1m after selling a third of the firm to institutions, writes John Willcock.
Neil Rotherham and Jonathan Engler are selling a third of their private company Clinphone to Mercury Asset Management's private equity division and HSBC Private Equity for pounds 3.3m.
The duo, who worked as doctors until four years ago, have developed an automated phone system which should cut the time taken to test new drugs.
Currently doctors involved in such trials have to fill in lengthy forms with their results, and the money tied up in such long-term trials are immense. Under Clinphone's system this bureaucracy is replaced by touch- tone phones. The doctors involved simply punch in their answers to a series of questions directly to the pharmaceutical company concerned.
This cuts the time taken for the trials and consequently increases the period during which the drug's patent can keep earning the pharmaceutical company money.
Jeremy Sharman, a director of MAM, says Clinphone is "one of the fastest growing companies I have ever been involved with. The projected figures are very bullish".
While the company will only complete its first trading year in February, it already has a blue chip client list which includes Glaxo and SmithKline Beecham, says Mr Sharman. The company is based in Nottingham and employs around 20 people. It was launched last year with a couple of hundred thousand pounds of family money.
Mr Sharman said it was possible the business may float either in London or New York, possibly in three years' time.
The Clinphone interactive phone technology already has 14 different languages in use in 30 countries. The company claims the system is efficient in ensuring that the patients being tested are randomly recruited, which is vital in clinical trials.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments